Arvind Sharma, MD
Cardiovascular Disease · Saint Joseph, MONPI 1588776793
Payments from drug & device makers
Across 174 payments — averaging $26.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$750
- Edwards Lifesciences$684
- Amgen$398
- Abiomed$340
- Johnson & Johnson$320
- Heartflow, Inc.$257
- plus $2K from 24 others
What the payments were for
- Grants$160%
- Food & beverage$4,51799%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 18 | $750 |
| Edwards Lifesciences | 12 | $684 |
| Amgen | 26 | $398 |
| Abiomed | 6 | $340 |
| Johnson & Johnson | 20 | $320 |
| Heartflow, Inc. | 7 | $257 |
| E.r. Squibb & Sons, L.L.C. | 11 | $232 |
| Pfizer | 14 | $215 |
| Abbott | 2 | $176 |
| AstraZeneca | 11 | $159 |
| Novartis | 6 | $133 |
| Penumbra, Inc. | 6 | $127 |
| Sanofi-aventis U.S. LLC | 8 | $125 |
| Biotronik Inc. | 4 | $91 |
| Lexicon Pharmaceuticals, Inc. | 1 | $91 |
| Altathera Pharmaceuticals LLC | 1 | $73 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $59 |
| Boston Scientific | 3 | $54 |
| Alnylam Pharmaceuticals Inc. | 3 | $47 |
| Cardiva Medical, Inc. | 2 | $39 |
| Shockwave Medical, Inc | 1 | $35 |
| Novo Nordisk | 1 | $24 |
| Merck | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Cook Medical LLC | 1 | $16 |
| Impulse Dynamics (USA) Inc. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
| Portola Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,557 in reported general payments places this provider in the 60th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 88 | $105,432 |
| XareltoRivaroxaban | 123 | $105,269 |
| EntrestoSacubitril/Valsartan | 79 | $97,466 |
| Repatha SureclickEvolocumab | 37 | $41,912 |
| JardianceEmpagliflozin | 40 | $41,336 |
| FarxigaDapagliflozin Propanediol | 30 | $33,394 |
| BrilintaTicagrelor | 38 | $30,882 |
| VascepaIcosapent Ethyl | 75 | $27,998 |
| Nifedipine ErNifedipine | 329 | $9,957 |
| Atorvastatin Calcium | 865 | $7,821 |
| ClopidogrelClopidogrel Bisulfate | 704 | $7,635 |
| Ranolazine ErRanolazine | 45 | $5,800 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 542 | $5,751 |
| Carvedilol | 596 | $5,061 |
| Metoprolol Succinate | 288 | $4,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $215 | $105,43288 claims |
| Johnson & JohnsonXarelto | $320 | $105,269123 claims |
| NovartisEntresto | $133 | $97,46679 claims |
| AstraZenecaFarxiga, Brilinta | $159 | $64,27668 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Saint Joseph
- Mikhail KosiborodKansas City$27.8M
- Mohammad TahirSaint Louis$2.7M
- John SpertusKansas City$2.3M
- Joshua MitchellSaint Louis$1.4M
- Nathan StitzielSaint Louis$1.2M
- Daniel KellySaint Louis$1.1M
- Georges ChahoudSaint Louis$967K
- Jiafu OuSaint Louis$853K
- William BowenSaint Louis$726K
- Omar AlmousalliFestus$690K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.